Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995356 | 1.00 | CETP (0.80) | CETP | |
| SCHEMBL992977 | 0.94 | CETP (0.71) | CETP | |
| SCHEMBL994098 | 0.94 | CETP (0.71) | CETP | |
| SCHEMBL992085 | 0.94 | CETP (0.83) | CETP | |
| SCHEMBL993097 | 0.94 | CETP (0.83) | CETP | |
| SCHEMBL993152 | 0.93 | CETP (0.70) | CETP | |
| SCHEMBL994948 | 0.93 | CETP (0.70) | CETP | |
| SCHEMBL994079 | 0.92 | CETP (0.70) | CETP | |
| SCHEMBL993631 | 0.92 | CETP (0.70) | CETP | |
| SCHEMBL993687 | 0.92 | CETP (0.69) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070282009-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC | 2007-12-06 | — | — | US | claimed |
| US-6723752-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-20030078264-A1 | (R)-chiral halogenated substituted N,N-bis-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-04-24 | — | — | US | claimed |
| US-20030050317-A1 | (R)-chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-03-13 | — | — | US | claimed |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-02-27 | — | — | US | claimed |
| US-20030027826-A1 | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-02-06 | — | — | US | claimed |
| US-20020177708-A1 | (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-28 | — | — | US | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2305217-B1 | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | BEND RES INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8703196-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | ABCB1, ABCG2, CYP3A7 | CETP 63/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | CETP 1214/4885 |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | ABCG2, ALB, SLCO1A2 | CETP 162/4885 |
| US-20030027826-A1 | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CETP 1/4885 |
| US-20020177708-A1 | (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885 |
| US-20030078264-A1 | (R)-chiral halogenated substituted N,N-bis-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885 |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PLTP | CETP 1/4885 |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885 |
| US-20030050317-A1 | (R)-chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CETP 1/4885 |
| US-20070282009-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.